Due to their relevance and promising clinical use, in this review, we will particularly focus on the role and biomarker utility of Fetuin-A, MGP and GRP, as well as the use of CPP measurements to reflect serum calcification inhibitory capacity as potential added value circulating VC biomarkers in CKD. The gene discussed is GRP; the disease is chronic kidney disease.